DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sulfasalazine
Sulfasalazine
Inflammatory Bowel Disease Irritable Bowel Syndrome
Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
Stems for Nonproprietary Drug Names
Sulfasalazine (Azulfidine)
Effect of IBD Medications on COVID-19 Outcomes: Results from an International Registry
Supplementary Materials Supplementary Methods Propensity Scores Were Calculated for Use As Weights Within the Inverse Probabilit
With Thanks & Gratitude
PATIENT FACT SHEET Sulfasalazine
Simultaneous HPLC Assay of Paracetamol and Sulfapyridine As
Effect of Sulfasalazine and Prednisolone Against Dextran Induced Ulcerative Colitis in Female Balb/C Mice
(12) United States Patent (10) Patent No.: US 7438,929 B2 Beckert Et Al
WHO Drug Information Vol. 03, No. 4, 1989
Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil
Risks of Inflammatory Bowel Disease Treatment with Glucocorticosteroids and Aminosalicylates
Estonian Statistics on Medicines 2013 1/44
Azulfidine (Sulfasalazine)
Learn About Sulfasalazine
Understanding IBD Medications and Side Effects Brochure
Top View
Therapeutic Class Overview Inflammatory Bowel Disease Agents
A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs Vs
Aminosalicylates
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
The Selection and Use of Essential Medicines
Drugs for Parasitic Infections (2013 Edition)
Common Antibiotics
Brand Generic Guide
Xct Inhibitor Sulfasalazine Depletes Paclitaxel‑Resistant Tumor Cells Through Ferroptosis in Uterine Serous Carcinoma
ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
5-ASA) (Mesalamine, Balsalazide, Sulfasalazine
View of the Incidence and Outcome of Severe Systemic Reactions to Sulfasalazine
2001 FSIS National Residue Program Blue Book
Salazopyrin Tablet: Each Tablet Contains 500 Mg Sulfasalazine
In Vitro to in Vivo Extrapolation for Drug-Induced Liver Injury Using a Pair Ranking Method
Neemmc Guidelines for Tablet Crushing and Administration Via Enteral Feeding Tubes
Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects
Factors Influencing Response to Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Section a Changed Classes/Guidelines
Low-Dose Glucocorticoid Therapy in Rheumatoid Arthritis. a Review on Safety: Published Evidence and Prospective Trial Data
Sulfasalazine
New Brunswick Drug Plans Formulary
Medication Coverage Policy
Quantification and Metabolite Identification of Sulfasalazine in Mouse Brain and Plasma Using Quadrupole-Time-Of-Flight Mass
Drug-Induced Hyperpigmentation: Review and Case Series
Irritable Bowel Syndrome: Emerging Approaches, Nutrition Solutions
IMPORTANT ADVICE to KEEP YOU SAFE from CORONAVIRUS Your Safety and the Continued Provision of the Care and Treatment You Need Is a Priority for the NHS
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Sulfasalazine
Treatment Patterns and Pharmacoutilization in Patients Affected by Rheumatoid Arthritis in Italian Settings
Rapid Review: Immunosuppression and COVID-19 Risk
Prior Authorization Group Description 5Ht3 Anti-Nausea Agent Bvd Determination
Each Asacol Delayed-Release Tablet for Oral Administration Contains 400 Mg of Mesalamine, an Anti-Inflammatory Drug
WHO Model List of Essential Medicines
University of Groningen Drug Use in Pregnancy Vroom, Fokaline
PROTECT Pregnancy Study- an Exploratory Study Of
Drug Allergy
Mesalazine and Other Aminosalicylates (Adults)
Cimzia Prior Authorization Request
PRAC Recommendations on Signals Adopted at the 11-14 June 2019 PRAC Meeting
Supplementary Table 1 As Described in the Methods Section, for Every Medication, Odds Ratios
Rationale for the Use of Rifaximin in Inflammatory Bowel Diseases Based on Clinical Trial Results
Rifaximin-Extended Intestinal Release Induces Remission in Patients With
Budesonide (Uceris®)
Switching Between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Al